/PRNewswire/ LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, announced today that its rapid COVID-19 antigen assay,.
Results in just 5 minutes from sample application, aids in fast clinical decision-making at point of care (POC), helping to inform treatment decisions and.
Strong Growth in Instruments Delivered to Customers and Continued Innovation on our Platform LONDON, May 11, 2022 /PRNewswire/ LumiraDx Limited (Nasdaq: LMDX), a next-generation point
LONDON, April 29, 2022 /PRNewswire/ LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its first quarter financial results
LumiraDx (NASDAQ:LMDX – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, “LumiraDx Limited is a point of care diagnostics company. Its testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent […]